| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 04/28/2022 | 1688.62% | HC Wainwright & Co. | $24 → $11 | Maintains | Buy |
| 03/30/2021 | 1688.62% | Cantor Fitzgerald | → $11 | Initiates Coverage On | → Overweight |
| 05/29/2020 | 387.8% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 10/22/2018 | 1526.02% | Northland Capital Markets | → $10 | Initiates Coverage On | → Outperform |
Aytu BioPharma Questions & Answers
The latest price target for Aytu BioPharma (NASDAQ: AYTU) was reported by HC Wainwright & Co. on April 28, 2022. The analyst firm set a price target for $11.00 expecting AYTU to rise to within 12 months (a possible 1688.62% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Aytu BioPharma (NASDAQ: AYTU) was provided by HC Wainwright & Co., and Aytu BioPharma maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aytu BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aytu BioPharma was filed on April 28, 2022 so you should expect the next rating to be made available sometime around April 28, 2023.
While ratings are subjective and will change, the latest Aytu BioPharma (AYTU) rating was a maintained with a price target of $24.00 to $11.00. The current price Aytu BioPharma (AYTU) is trading at is $0.62, which is out of the analyst's predicted range.